Interventional Radiology Imaging

What Is the Best Intervention for Bleeding Gastric Varices with a Gastrorenal Shunt?

·
What Is the Best Intervention for Bleeding Gastric Varices with a Gastrorenal Shunt?

It’s 2 AM, and you are managing a patient in the ICU with known cirrhosis who presented with a significant upper GI bleed. Endoscopy confirmed the source: large gastric varices. The patient is stabilized for now, but the contrast-enhanced CT you ordered is up on the screen, clearly showing large, tortuous gastric varices fed by a prominent gastrorenal shunt. With a Model for End-stage Liver Disease (MELD) score of 20, the patient’s liver function is severely compromised, making the next management decision critical. This article details the clinical workflow for this exact scenario, explaining why the American College of Radiology (ACR) rates Balloon-occluded Retrograde Transvenous Obliteration (BRTO) as Usually appropriate.

Who Fits This Clinical Scenario for Gastric Variceal Bleeding?

This guidance is specifically for a patient who meets a precise set of clinical and anatomic criteria. The recommendations discussed here apply directly to a cirrhotic patient with active or recent bleeding from large, high-flow gastric varices, a MELD score of approximately 20, and, critically, a large gastrorenal shunt identified on cross-sectional imaging like CT or MRI.

It is crucial to distinguish this presentation from similar, but distinct, clinical problems that require different management strategies:

  • Patients with Refractory Ascites or High-Pressure Esophageal Varices: If the dominant clinical problem is fluid overload or bleeding from esophageal varices, a procedure that decompresses the entire portal system, like a Transjugular Intrahepatic Portosystemic Shunt (TIPS), may be prioritized over a targeted therapy like BRTO.
  • Patients with Severe Hepatic Encephalopathy (HE): While this scenario does not specify HE, its presence would further strengthen the case for BRTO, as TIPS is known to worsen HE. A patient with a lower MELD score but significant HE also fits a distinct management pathway.
  • Patients with Splenic Vein Thrombosis: If the gastric varices are caused by isolated splenic vein occlusion (so-called “left-sided” or “sinistral” portal hypertension), the underlying pathophysiology is different. The treatment is aimed at the source, often involving splenectomy or splenic artery embolization, not BRTO or TIPS.

What Is the Primary Management Goal in This Scenario?

In this patient, the diagnosis of bleeding gastric varices is already established. The clinical challenge is not diagnostic but therapeutic: selecting the intervention with the highest chance of durable hemostasis and the lowest risk of complications. The “differential” is one of therapeutic strategy, guided by the patient’s specific anatomy and physiology.

Hemorrhage from a High-Flow, Shunt-Fed Varix
The central issue is the large gastrorenal shunt. This naturally formed vessel acts as a low-resistance outflow tract, diverting a high volume of high-pressure portal venous blood directly into the systemic circulation via the left renal vein. This hemodynamic setup creates large, tense varices that are prone to rupture and massive bleeding. The primary therapeutic goal must be the direct elimination of this specific vascular circuit to stop the bleeding and prevent recurrence.

Balancing Hemostasis with Systemic Consequences
The patient’s MELD score of 20 signifies substantial liver dysfunction and a high short-term mortality risk. Any intervention must be weighed against its potential to further destabilize the patient. A procedure that stops the bleed but precipitates liver failure or intractable hepatic encephalopathy is not a clinical success. The ideal intervention achieves hemostasis while preserving, or even improving, hepatic function and perfusion.

Risk of Worsening Portal Hypertension Post-Procedure
A critical consideration is the effect of closing the gastrorenal shunt. This shunt acts as a “pop-off” valve, decompressing the portal system. Occluding it will redirect blood flow and can acutely increase portal pressure. This may lead to the development or worsening of esophageal varices or ascites. The clinical team must anticipate and be prepared to manage these potential sequelae.

Why Is BRTO Usually Appropriate for a Cirrhotic Patient with a Gastrorenal Shunt?

For this specific presentation, the ACR Appropriateness Criteria rate Balloon-occluded Retrograde Transvenous Obliteration (BRTO) as Usually appropriate. This procedure is designed to directly address the anatomic cause of the bleeding: the high-flow shunt.

During BRTO, an interventional radiologist navigates a catheter, typically from the femoral vein, into the left renal vein and then retrogradely into the gastrorenal shunt. A balloon is inflated to occlude the shunt’s outflow, and a sclerosant agent is injected to induce thrombosis of the shunt and the connected gastric varices. This directly obliterates the bleeding vessels.

The rationale for this recommendation is multi-faceted:

  • High Efficacy for Hemostasis: BRTO has a very high rate of technical success and is extremely effective at controlling acute bleeding and preventing re-bleeding from gastric varices associated with a gastrorenal shunt. It physically eliminates the problematic vascular anatomy.
  • Preservation of Antegrade Portal Flow: Unlike TIPS, which diverts portal blood away from the liver, BRTO closes a spontaneous shunt. This increases blood flow to the liver, which can help preserve or, in some cases, improve hepatic function.
  • Reduced Risk of Hepatic Encephalopathy: By closing a major portosystemic shunt, BRTO reduces the amount of unfiltered blood reaching the systemic circulation, which can improve or stabilize hepatic encephalopathy. This is a significant advantage over TIPS, which often worsens it.

Why Alternative Procedures Are Rated Lower

While endoscopic management is also rated Usually appropriate for initial stabilization, BRTO is often considered for more definitive, long-term control in this anatomic setting. Other interventional options are rated lower for specific reasons:

  • TIPS: Rated May be appropriate. A TIPS procedure effectively decompresses the portal system, which can control variceal bleeding. However, in a patient with a MELD score of 20, the risk of precipitating severe hepatic encephalopathy or post-procedural liver failure is substantial. It is generally reserved for patients who are not candidates for BRTO or who have other compelling indications for portal decompression, such as refractory ascites.
  • Partial Splenic Embolization: Rated May be appropriate. This procedure can reduce portal inflow and pressure by occluding a portion of the splenic artery. However, it does not directly address the high-flow outflow shunt and is less definitive for controlling bleeding from large gastric varices in this context. It is more often used as an adjunct or in different clinical scenarios.

What’s Next After BRTO? Downstream Workflow

A successful BRTO procedure is a critical step, but management does not end there. The post-procedure workflow is focused on monitoring for complications and managing the consequences of altered portal hemodynamics.

  • If the procedure is successful: The immediate next step is monitoring in an ICU or step-down setting. The patient should be watched closely for signs of re-bleeding, though this is uncommon. The primary focus shifts to monitoring for the consequences of increased portal pressure. This includes surveillance for new or worsening ascites, which may require intensified diuretic therapy, and esophageal varices. A follow-up endoscopy is typically scheduled within a few weeks to months to assess the esophageal varices and determine if banding is needed.
  • If the procedure is technically unsuccessful: In the rare event that the gastrorenal shunt cannot be cannulated or occluded, the patient remains at high risk for re-bleeding. The next step is to reconsider the alternative therapies. A discussion between gastroenterology, interventional radiology, and hepatology is crucial to weigh the risks and benefits of proceeding with TIPS versus attempting further endoscopic management.
  • If new or worsening esophageal varices develop: This is an expected potential consequence of BRTO. The patient should be managed according to standard guidelines for esophageal variceal prophylaxis, which typically involves endoscopic variceal ligation (banding) and non-selective beta-blocker therapy.

Pitfalls to Avoid (and When to Get Help)

Navigating this complex clinical scenario requires avoiding several common pitfalls:

  • Misidentifying the Shunt Anatomy: Not all shunts are simple gastrorenal shunts. Complex anatomy with multiple inflow or outflow vessels can lead to incomplete obliteration and treatment failure. Careful review of pre-procedural CT imaging is essential.
  • Underestimating the Risk of Worsened Portal Hypertension: Failing to anticipate and proactively manage post-BRTO ascites or esophageal varices can lead to new complications. Ensure a clear plan for post-procedure surveillance is in place.
  • Delaying Definitive Treatment: While initial endoscopic therapy can be life-saving, relying on it alone in a patient with a large gastrorenal shunt carries a high risk of re-bleeding. Prompt consultation with interventional radiology for definitive treatment is key.

If the patient develops refractory ascites or recurrent esophageal variceal bleeding after BRTO, this represents a significant clinical escalation. This situation requires an urgent multidisciplinary discussion to consider salvage TIPS or evaluation for liver transplantation.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to the interventional management of gastric varices, please see our parent topic hub article. For additional decision support and technical guidance, the following GigHz resources are available:

Frequently Asked Questions

Why is BRTO preferred over TIPS for a patient with a MELD score of 20?

BRTO is generally preferred because it directly obliterates the bleeding varix and associated shunt without diverting portal blood flow away from the liver. This preserves or even improves liver perfusion and carries a much lower risk of worsening hepatic encephalopathy, which is a major concern in a patient with a high MELD score and significant liver dysfunction. TIPS, while effective at reducing portal pressure, has a higher risk of precipitating liver failure or severe encephalopathy in this patient population.

What if the patient’s CT did not show a gastrorenal shunt?

The presence of a large gastrorenal shunt is the key indication for BRTO. If no suitable shunt is identified, BRTO is not technically feasible. The management strategy would then shift towards other options. Endoscopic therapy with cyanoacrylate glue injection would be a primary consideration. If that fails or is not possible, a TIPS procedure would be the next likely step to decompress the portal system and reduce pressure in the varices.

Can BRTO worsen ascites or esophageal varices?

Yes, this is a known and expected potential consequence. The gastrorenal shunt acts as a major decompressive pathway for the portal system. By closing it, BRTO can acutely increase portal pressure, which may lead to the formation or worsening of ascites and esophageal varices. Patients must be monitored closely for these complications post-procedure and managed with diuretics and endoscopic surveillance with banding as needed.

Is there a role for surgery in this specific scenario?

Surgical management, such as a surgical shunt or devascularization procedure, is rated as ‘May be appropriate’ by the ACR but is rarely performed in this setting. For a patient with a MELD score of 20, the morbidity and mortality of major abdominal surgery are extremely high. Minimally invasive endovascular procedures like BRTO or TIPS are almost always preferred due to their lower procedural risk.

How does the sclerosant used in BRTO work and what are the risks?

BRTO typically uses a sclerosant agent, such as ethanolamine oleate, mixed with an imaging contrast agent. After the outflow is blocked by the balloon, this mixture is injected into the static blood within the varix and shunt. The sclerosant damages the endothelial lining of the vessels, triggering thrombosis and eventual obliteration. The main risks associated with the sclerosant include hemolysis (breakdown of red blood cells), which can cause renal injury, and non-target embolization if the agent escapes the intended vascular territory.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026